Locations:
Search IconSearch

Is mTESE Right For Your Patient?

Predicting outcomes for a male infertility treatment

650×450-Vij-Surgery

There are relatively few options for men with nonobstructive azoospermia (NOA), a severe form of infertility where no sperm is present in the ejaculate, but new data may help men decide if surgery is the right treatment for them.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Currently, the primary intervention to treat NOA is microdissection testicular sperm extraction (mTESE), a procedure where surgeons carefully search the testicle for small quantities of sperm using an operating microscope.

Scott Lundy, MD, PhD, a fifth-year resident in Cleveland Clinic’s Glickman Urological and Kidney Institute and first-author of a new study notes, “The surgery itself is not a major undertaking for the patient, but sperm is found in about half of men who undergo the procedure. The trouble is we do not know ahead of time who is likely to have a positive outcome.” Complicating the decision-making process for couples is the fact that this surgery is generally not covered by insurance.

Positive association between semen pH and sperm retrieval

Dr. Lundy led a retrospective review of 118 men who underwent a total of 129 mTESE procedures at Cleveland Clinic from 2012 to 2018. The overall sperm retrieval rate was 57%. Univariate analysis showed an association between semen pH and successful sperm retrieval (p=0.035). The multivariable analysis identified semen volume, semen pH levels and follicle-stimulating hormone (FSH) as predictors of successful sperm retrieval.

“While this is not the first study to examine predictive outcomes of mTESE, it is the first, to our knowledge, to explore pH levels as a clinical variable,” says Sarah Vij, MD, urologist in Cleveland Clinic’s Glickman Urological and Kidney Institute and senior author of the study.

In fact, this finding surprised the team. “We can’t quite explain that yet. We are conducting basic science studies to look at the microbiome and other areas that might provide a casual explanation or mechanism,” she says.

Advertisement

What is understood is that some combination of those three characteristics – semen volume, semen pH levels and FSH – combined together provide modest predictive value on whether or not this surgery will be successful.

Calculating outcomes for patients

With this data, the team produced a predictive nomogram and made the calculator publicly available. Right now it’s being piloted by providers across the country, and the feedback has been positive. Dr. Lundy hopes this can be another tool for patients and clinicians.

“The predictive model is a tool to support the clinical decision-making process during what is typically a difficult time men and their families,” he says. “It should be used in a clinical context, where the patient and provider can individualize care.”

In the same way the PSA test has improved risk calculations for prostate cancer, the investigators hope this model will project the likelihood of sperm retrieval through mTESE.

What’s next: describing the etiology of infertility

Dr. Lundy, who plans to publish the results of this study later this year, notes that understanding the underlying pathology is equally important to identify clinical variables. This study lays a framework for investigating pH levels at a mechanistic level.

For example, the physicians believe bacteria, fungi or viruses may play a role in predisposing some men to infertility issues. The investigators are in the process of analyzing data from a prospective trial designed to differentiate gut microbiota of fertile and non-fertile men.

“We see so many young men who struggle mightily with infertility issues. It’s an issue that deserves our attention and resources,” he says.

Advertisement

Related Articles

CT scan of female patient bladder cancer
November 26, 2024/Urology & Nephrology/Urology
Use of Interim Imaging To Preserve Eligibility for Vaginal-Sparing Cystectomy

Retrospective study evaluates clinical upstaging during neoadjuvant treatment

Microscopic view of bladder cancer with variant histology
November 19, 2024/Urology & Nephrology/Urology
Nonmuscle Invasive Bladder Cancer With Variant Histology: When To Consider a Bladder-Sparing Approach

Retrospective study finds acceptable cancer control among most histologic subtypes with intravesical therapy

Single-port robot docked in the operating room
November 12, 2024/Urology & Nephrology/Urology
Single-Port Pyeloplasty in a Pediatric Patient: A Novel Surgical Technique

Revolutionizing pediatric urology with a new, less invasive approach

Physician smiles at patient in a preoperative setting
September 12, 2024/Urology & Nephrology/Urology
Improving the Bladder Cancer Survivorship Experience for Women

What updated techniques, counseling and a changing workforce could mean

Surgeons in the operating room with the single-port robot
Novel Single-Port Robotic Urology Surgery Surpasses 1,000 Cases

Applications, outcomes and untapped potential

Photo of Dr. Bajic
Counseling Your Patients on SGLT-2 Inhibitors and Adverse Urologic Outcomes

Retrospective study shows SGLT-2 inhibitors may lead to worse urologic outcomes

Illustration of red blood cells in motion
Review Underscores Impact of Red Blood Cell Disorders on Male Reproduction

Early, individualized diagnosis and comprehensive management key to preserving fertility

UTI bacteria and artificial intelligence
AI Algorithms Accurately Predict Antibiotic Resistance in UTI

Up to 3 days faster than waiting for urine culture results

Ad